Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS; HSCSW), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of Artificial Intelligence (AI), announced today that the Israel Patent Office has granted it a patent.

“Artificial intelligence is transforming what’s possible, and at HeartSciences, we are at the forefront of changing what’s possible with an ECG by applying AI to make it a far more valuable screening tool for heart disease detection to save lives,” said Andrew Simpson, Chief Executive Officer of HeartSciences. With more patents granted per capita than anywhere else in the world, Israel is a hotbed for medical device innovation. This patent award strengthens our intellectual property and validates our position as a technology innovator. The protection of our intellectual property and patents is central to our strategy because they have intrinsic value and are expected to provide a significant competitive advantage as we move toward commercialization.”

Every week, millions of ECGs are performed worldwide, and the ECG is by far the most common cardiac test. Despite this, cardiovascular disease claims 17.9 million lives each year, accounting for an estimated 32% of all deaths worldwide. The MyoVista® provides all conventional ECG information as well as an AI algorithm for detecting cardiac dysfunction. Conventional ECGs have historically had a limited, if any, role in the evaluation of cardiac dysfunction, which has significantly reduced their role in the screening of heart disease.

HeartSciences has received nine US patents and 31 international patents, totaling 40 granted patents. The company has 8 more patents pending in the US and internationally. International patents have been issued in a number of key countries, including China, Brazil, Canada, India, South Korea, Mexico, and key European markets such as Germany, France, the United Kingdom, Italy, and the Netherlands.